Compound K, a novel ginsenoside metabolite, inhibits adipocyte differentiation in 3T3-L1 cells: Involvement of angiogenesis and MMPs

Biochemical and Biophysical Research Communications

Volumn 422, Issue 2, 2012, Pages 263-267

  Park, Dongmin ^a   Yoon, Michung ^a  

^a Mokwon University   (South Korea)

Author keywords

Adipocyte; Adipogenesis; Ginseng; Matrix metalloproteinase; Obesity

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; GELATINASE B; GINSENOSIDE; LEPTIN; MATRIX METALLOPROTEINASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; THROMBOSPONDIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSCRIPTION FACTOR AP 2; VASCULOTROPIN A;

ADIPOCYTE; ADIPOGENESIS; ANGIOGENESIS; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; LIPID STORAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

3T3-L1 CELLS; ADIPOCYTES; ADIPOGENESIS; ANIMALS; CCAAT-ENHANCER-BINDING PROTEINS; FATTY ACID-BINDING PROTEINS; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION; GINSENOSIDES; LIPID METABOLISM; MATRIX METALLOPROTEINASES; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; PPAR GAMMA; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

PANAX GINSENG;

EID: 84861705073     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.04.142     Document Type: Article

References (28)

1. Gillis C.N. Panax ginseng pharmacology: a nitric oxide link?. Biochem. Pharmacol. 1997, 54:1-8.
2. Attele A.S., Wu J.A., Yuan C.S. Ginseng pharmacology: multiple constituents and multiple actions. Biochem. Pharmacol. 1999, 58:1685-1693.
3. Lu J.M., Yao Q., Chen C. Ginseng compounds: an update on their molecular mechanisms and medical applications. Curr. Vasc. Pharmacol. 2009, 7:293-302.
4. Sato K., Mochizuki M., Saiki I., et al. Inhibition of tumor angiogenesis and metastasis by a saponin of Panax ginseng, ginsenoside-Rb2. Biol. Pharm. Bull. 1994, 17:635-639.
5. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995, 1:27-31.
6. Yue P.Y., Wong D.Y., Wu P.K., et al. The angiosuppressive effects of 20(R)-ginsenoside Rg3. Biochem. Pharmacol. 2006, 72:437-445.
7. Sengupta S., Toh S.A., Sellers L.A., Skepper J.N., Koolwijk P., Leung H.W., Yeung H.W., Wong R.N., Sasisekharan R., Fan T.P. Modulating angiogenesis: the yin and the yang in ginseng. Circulation 2004, 110:1219-1225.
8. Xu T.M., Cui M.H., Xin Y., Gu L.P., Jiang X., Su M.M., Wang D.D., Wang W.J. Inhibitory effect of ginsenoside Rg3 on ovarian cancer metastasis. Chin. Med. J. 2008, 121:1394-1397.
9. Hasegawa H., Sung J.H., Matsumiya S., et al. Main ginseng saponin metabolites formed by intestinal bacteria. Planta Med. 1996, 62:453-457.
10. Jeong A., Lee H.J., Jeong S.J., Lee H.J., Lee E.O., Bae H., Kim S.H. Compound K inhibits basic fibroblast growth factor-induced angiogenesis via regulation of p38 mitogen activated protein kinase and AKT in human umbilical vein endothelial cells. Biol. Pharm. Bull. 2010, 33:945-950.
11. Choi H.H., Jong H.S., Park J.H., et al. A novel ginseng saponin metabolite induces apoptosis and down-regulates fibroblast growth factor receptor 3 in myeloma cells. Int. J. Oncol. 2003, 23(4):1087-1093.
12. Jung S.H., Woo M.S., Kim S.Y., et al. Ginseng saponin metabolite suppresses phorbol ester-induced matrix metalloproteinase-9 expression through inhibition of activator protein-1 and mitogen-activated protein kinase signaling pathways in human astroglioma cells. Int. J. Cancer 2006, 118:490-497.
13. Bouloumié A., Lolmède K., Sengenès C., et al. Angiogenesis in adipose tissue. Ann. Endocrinol. (Paris) 2002, 63:91-95.
14. Cao Y. Angiogenesis modulates adipogenesis and obesity. J. Clin. Invest. 2007, 117:2362-2368.
15. Cao Y. Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases. Nat. Rev. Drug. Discov. 2010, 9:107-115.
16. Bouloumié A., Sengenès C., Portolan G., Galitzky J., Lafontan M. Adipocyte produces matrix metalloproteinases 2 and 9: involvement in adipose differentiation. Diabetes 2001, 50:2080-2086.
17. Kawaguchi N., Toriyama K., Nicodemou-Lena E., Inou K., Torii S., Kitagawa Y. De novo adipogenesis in mice at the site of injection of basement membrane and basic fibroblast growth factor. Proc. Natl. Acad. Sci. USA 1998, 95:1062-1066.
18. Christiaens V., Lijnen H.R. Role of the fibrinolytic and matrix metalloproteinase systems in development of adipose tissue. Arch. Physiol. Biochem. 2006, 112(4-5):254-259.
19. Chavey C., Mari B., Monthouel M.N., Bonnafous S., Anglard P., Van Obberghen E., Tartare-Deckert S. Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation. J. Biol. Chem. 2003, 278:11888-11896.
20. Maquoi E., Munaut C., Colige A., et al. Modulation of adipose tissue expression of murine matrix metalloproteinases and their tissue inhibitors with obesity. Diabetes 2002, 51:1093-1101.
21. Couillard C., Mauriège P., Imbeault P., et al. Hyperleptinemia is more closely associated with adipose cell hypertrophy than with adipose tissue hyperplasia. Int. J. Obes. Relat. Metab. Disord. 2000, 24:782-788.
22. Crandall D.L., Hausman G.J., Kral J.G. A review of the microcirculation of adipose tissue: anatomic, metabolic, and angiogenic perspectives. Microcirculation 1997, 4:211-232.
23. Rosen E.D., Spiegelman B.M. Molecular regulation of adipogenesis. Annu. Rev. Cell Dev. Biol. 2000, 16:145-171.
24. Rosen E.D., Sarraf P., Troy A.E., et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell 1999, 4:611-617.
25. Fukumura D., Ushiyama A., Duda D.G., et al. Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesis. Circ. Res. 2003, 93:e88-e97.
26. Bråkenhielm E., Cao R., Gao B., et al. Angiogenesis inhibitor, TNP-470, prevents diet-induced and genetic obesity in mice. Circ. Res. 2004, 94:1579-1588.
27. Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., Fahrig M., Vandenhoeck A., Harpal K., Eberhardt C., Declercq C., Pawling J., Moons L., Collen D., Risau W., Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996, 380:435-439.
28. Armstrong L.C., Bornstein P. Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol. 2003, 22:63-71.